Edition:
India

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

8.20USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$8.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
260,877
52-wk High
$15.35
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

TG Therapeutics Announces Initiation Of Randomized Phase II Trial In Follicular Lymphoma
Monday, 27 Nov 2017 

Nov 27 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS ANNOUNCES INITIATION OF NATIONAL CANCER INSTITUTE/SWOG-SPONSORED RANDOMIZED PHASE II TRIAL IN FOLLICULAR LYMPHOMA.  Full Article

TG Therapeutics qtrly net loss per common share $0.48
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - TG Therapeutics Inc ::TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results.TG therapeutics inc - qtrly net loss per common share $0.48.Q3 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.TG therapeutics inc - believes cash and cash equivalents will be sufficient to fund planned operations through 2018​.  Full Article

TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial
Monday, 16 Oct 2017 

Oct 16 (Reuters) - TG Therapeutics Inc : :TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial.TG Therapeutics Inc - ‍targeting an NDA/BLA filing for combination of TGR-1202 + TG-1101 in 2H18​.TG Therapeutics Inc - ‍top-line ORR data from UNITY-CLL trial expected in 2Q18​.  Full Article

TG Therapeutics ‍says FDA confirms accelerated approval for TG-1101 based on overall response rate a review issue
Monday, 16 Oct 2017 

Oct 16 (Reuters) - TG Therapeutics Inc : :TG Therapeutics provides update on fda meeting for genuine phase 3 trial.TG Therapeutics - co ‍has met with U.S. FDA regarding use of results from genuine phase 3 trial to support bla filing for approval of TG-1101​.TG Therapeutics Inc - ‍fda confirmed that accelerated approval for TG-1101 based on overall response rate would be a review issue ​.TG Therapeutics - ‍FDA asked co to consider future available therapy in risk/benefit analysis in future BLA filing that may impact accelerated approval.TG Therapeutics - co, FDA also discussed potential use of progression free survival results from genuine trial to support full approval of TG-1101​.TG Therapeutics Inc - ‍plans to have a follow-up meeting with FDA to discuss use of PFs endpoint in more detail before end of year​.  Full Article

TG Therapeutics amends phase 3 clinical trial
Thursday, 13 Oct 2016 

TG Therapeutics Inc : TG Therapeutics Inc. Amends genuine phase 3 clinical trial to accelerate study completion by revising primary endpoint to overall response rate . TG Therapeutics Inc- enrollment expected to be completed before year end 2016 with top-line data available in first half of 2017 . TG Therapeutics - if results of revised genuine study are positive, plans to file a bla for accelerated approval based on outcome of pre-BLA meeting . FDA agrees that overall response rate (orr) data from revised genuine study can be used to request pre-BLA meeting . TG Therapeutics - amendments expected to save co more than $10 million over next 2 years, and allow company to focus its resources on unity-CLL program . TG Therapeutics Inc- company believes it could file a BLA in first half of 2018 .TG Therapeutics Inc - target enrollment for genuine phase 3 trial has been reduced to approximately 120 randomized patients.  Full Article

TG Therapeutics Q2 GAAP loss per share $0.33
Monday, 8 Aug 2016 

TG Therapeutics Inc : TG Therapeutics Inc announces second quarter 2016 financial results and business update . Q2 GAAP loss per share $0.33 .Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.  Full Article

TG Therapeutics says first patient enrolled in UNITY-DLBCL phase 2b trial
Tuesday, 7 Jun 2016 

TG Therapeutics Inc :Announces first patient enrolled in registration-directed UNITY-DLBCL phase 2b trial.  Full Article

TG Therapeutics enters into collaboration to develop and commercialize Novel BET inhibitors
Friday, 27 May 2016 

TG Therapeutics Inc : Enters into a global collaboration to develop and commercialize Novel BET inhibitors developed by Jubilant Biosys for the treatment of hematological malignancies . Under terms of agreement, TG Therapeutics will pay an up-front licensing fee of $1 million . Additional payments contingent on certain milestones of up to approximately $177 million .TG Therapeutics will also provide funding to support certain targeted research efforts at Jubilant Biosys.  Full Article

TG Therapeutics Q1 loss per share $0.28
Wednesday, 11 May 2016 

TG Therapeutics Inc : Reaffirming 2016 milestones . TG Therapeutics, Inc. Announces first quarter 2016 financial results and business update . Q1 loss per share $0.28 .Q1 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-TG Therapeutics qtrly net loss per common share $0.48

* TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results